Intense Pulsed Light Therapy with Optimal Pulse Technology as an Adjunct Therapy for Moderate to Severe Blepharitis-Associated Keratoconjunctivitis
Table 1
Comparison of primary outcome measures.
Items
Groups
V0
V1
V2
V3
V4
Quality of meibum (upper eyelid)
Treatment group
15.83 ± 4.43
12.17 ± 4.59
7.69 ± 3.35
3.79 ± 2.23
2.86 ± 1.44
<0.001
Control group
15.05 ± 3.24
11.50 ± 2.99
9.82 ± 2.84
7.09 ± 2.71
5.77 ± 1.74
<0.001
0.465
0.541
0.014
<0.001
<0.001
Quality of meibum (lower eyelid)
Treatment group
13.07 ± 4.92
9.00 ± 5.08
6.17 ± 3.89
3.43 ± 2.96
2.55 ± 1.61
<0.001
Control group
13.14 ± 4.97
10.14 ± 4.00
8.82 ± 3.29
6.77 ± 2.78
4.59 ± 1.87
<0.001
0.960
0.366
0.008
<0.001
<0.001
Expressibility of the Meibomian glands (upper eyelid)
Treatment group
1.62 ± 0.76
1.14 ± 0.65
0.60 ± 0.50
0.05 ± 0.22
0.10 ± 0.30
<0.001
Control group
1.73 ± 0.53
1.68 ± 0.57
1.27 ± 0.45
1.18 ± 0.59
1.18 ± 0.50
<0.001
0.052
0.002
<0.001
<0.001
<0.001
Expressibility of the Meibomian glands (lower eyelid)
Treatment group
1.67 ± 0.57
0.95 ± 0.62
0.55 ± 0.50
0.05 ± 0.22
0.00 ± 0.00
<0.001
Control group
1.91 ± 0.53
1.55 ± 0.51
1.14 ± 0.56
1.00 ± 0.62
0.73 ± 0.70
<0.001
0.102
<0.001
<0.001
<0.001
<0.001
Changes of eyelid margin (upper eyelid)
Treatment group
2.67 ± 0.72
2.31 ± 0.71
1.69 ± 0.71
1.21 ± 0.81
0.71 ± 0.71
<0.001
Control group
2.68 ± 0.65
2.36 ± 0.49
2.05 ± 0.49
1.45 ± 0.51
0.91 ± 0.43
<0.001
0.934
0.752
0.041
0.212
0.242
Changes of eyelid margin (lower eyelid)
Treatment group
2.31 ± 0.60
1.90 ± 0.66
1.10 ± 0.76
0.60 ± 0.66
0.31 ± 0.47
<0.001
Control group
2.50 ± 0.67
2.18 ± 0.50
1.55 ± 0.67
1.18 ± 0.59
0.68 ± 0.57
<0.001
0.254
0.088
0.022
0.001
0.007
value of one-way repeated measure analysis of variance to compare data for each group at different time points; value of multivariate analysis to compare the treatment and control groups at a specific time point.
